Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07647432 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV

Study acronym: HEME-25
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 3 changed
See other at-risk trials from University of Illinois at Chicago

Record History

  1. Primary endpoint(s) modified Phase changed: Phase 2/3 → Phase 1 · Eligibility criteria shortened, about 112 words · Secondary endpoints revised (4) · 2 more Show 5 more changesShow less
    • Phase changed: Phase 2/3 → Phase 1
    • Eligibility criteria shortened, about 112 words
    • Secondary endpoints revised (4)
    • Study description expanded, about 3 words
    • Study title expanded, about 2 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm feasibility trial in which patients with histologically confirmed plasmablastic lymphoma (PBL) with or without HIV, who have achieved a Complete Response or Partial Response after definitive frontline chemotherapy, will receive Elranatamab (Elra) consolidation.
Trial Details
NCT Number NCT07647432
Lead Sponsor University of Illinois at Chicago
Collaborators: Pfizer
Conditions Plasmablastic Lymphoma, HIV, Consolidation
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov